|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||85.32 - 86.28|
|52 Week Range||74.00 - 89.09|
|PE Ratio (TTM)||40.69|
|Earnings Date||Jan 31, 2018|
|Forward Dividend & Yield||2.25 (2.62%)|
|1y Target Est||92.36|
Jan.09 -- David Ricks, chairman and chief executive officer at Eli Lilly & Co., discusses pricing pressures, the drug Trulicity, and the company's commitment to diabetes research. He speaks with Erik Schatzker on "Bloomberg Markets" from the JPMorgan Health Care conference in San Francisco.
Regularly affected by the ever-changing regulatory environment, the pharmaceutical and biotech industry is not one for producing the most stable cash flow. Thus, investors don’t usually associate this industry withRead More...
GREENFIELD, Ind., Jan. 18, 2018 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY), received two of the top honors in both food and companion animal innovation from Animal Pharm, a leading industry publication. During the 2017 award cycle, Galliprant (grapiprant tablets) was named Animal Pharm's Best Companion Animal Product and Clynav took top honors as best food animal product. Designed to honor achievements within the animal health sector during a calendar year, Animal Pharm's awards are decided by an independent panel of industry experts.
LEAWOOD, Kan., Jan. 18, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced GALLIPRANT® (grapiprant tablets) was named Animal Pharm's Best Companion Animal Product for 2017. Galliprant was made commercially available to veterinarians in January 2017 through a license and collaboration agreement with Elanco Animal Health, a division of Eli Lilly and Company (LLY). Galliprant provides targeted pain control from the earliest diagnosed stages of canine osteoarthritis and is the first piprant (a prostaglandin receptor antagonist) approved for use in veterinary medicine.
A U.S. Senate committee on Wednesday voted to move forward the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar's nomination, with all but one Democrat opposing. To receive final confirmation Azar will have to receive a majority vote in the 100-seat Senate, which Republicans control with 51 seats.
A key Senate committee on Wednesday voted to advance the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar's nomination with all but one Democrat opposing. To receive final confirmation Azar will have to receive a majority vote in the 100-seat Senate, which Republicans control with 51 seats.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.
Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.
The case for buying shares of Eli Lilly and Co (NYSE: LLY ) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes ...
Big pharmaceutical stocks are moving in disparate directions on Tuesday, with Merck (MRK) rising on good news while Eli Lilly (LLY) was falling after a downgrade. Merck is higher after late-stage trial data showed that Keytruda, when used with two chemotherapy drugs, was successful as a first-line treatment for lung cancer. While the blockbuster drug is already approved for use for cancer treatment, including lung cancer, the results were good news, as Merck and other Big Pharma companies are racing to bring new lung-cancer treatment options to market. As for Eli Lilly, Goldman Sachs' Jami Rubin and her team downgraded the stock from Buy to Neutral, writing that while they are still bullish on the company's long term, they're concerned that the bull thesis is well understood and already reflected in the stock's valuation. Moreover, Rubin argues, the risk to Lilly's diabetes franchise, particularly Trulicity--the company's biggest and fastest growth driver--isn't fully appreciated by the market, and that could cause downside to consensus estimates.
Outcomes on these three clinical trials in diabetes this year could change the way the disease is treated going into the next decade.
Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.
GREENFIELD, Ind., Jan. 11, 2018 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (LLY), named Sarena Lin as senior vice president, North America Operations and Global Strategy, joining Elanco's Leadership Team and reporting to Elanco president, Jeffrey Simmons.
LEAWOOD, Kan., Jan. 11, 2018 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY) and Aratana Therapeutics, Inc. (PETX), today announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union. Elanco has exclusive rights to develop, manufacture, market and commercialize Galliprant globally, and it co-promotes the product with Aratana in the United States. Founded in 1954, Elanco is a division of Eli Lilly and Company.
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, indicated on Tuesday he supported a Republican bid to overhaul Medicaid and again vowed to tackle high drug prices. Azar appeared before the Senate Finance Committee on Tuesday, which will ultimately decide whether to move his nomination forward. Azar also vowed to uphold Obamacare as long as it remained the law but said that the program needed changes.
WASHINGTON (AP) — Empowering Medicare to negotiate drug prices could leave patients with reduced access to medications, President Donald Trump's pick for health secretary warned Tuesday.
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.